Document Type : Original Article
Authors
- . Shahram Taheri 1
- . Ali Asghar Pilehvarian 2
- . Nafiseh Akbari 1
- . Samane Musavi 2
- . Afsoon Emami Naeini 1
1 Department of Internal Medicine, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Biology, Payame Noor University, Isfahan, Iran
Abstract
Objective: Patients on hemodialysis (HD) have a high risk for cardiovascular morbidity
and mortality. Cardiac troponins are biomarkers for diagnosing acute myocardial
injury or infarction. There is considerable controversy that exists in the frequency and
significance of cardiac troponins in predicting cardiac injury and ischemia in HD patients.
Methods: In this cross‑sectional study, all HD patients more than 18‑year‑old, who
were at least 3 months under HD, and had no sign and symptom of active cardiovascular
disease (CVD), in two HD centers were enrolled. One hundred and one patients fulfilled
the inclusion criteria. Blood sample for cardiac troponin I (cTnI) was drown before
the initiation of HD session during their routine monthly blood testing from patients’
vascular access arterial line. cTnI levels were measured by a high‑sensitivity assay,
VIDAS troponin I Ultra kit, and correlated with patients’ demographic, clinical, and
laboratory results.
Findings: The patients’ different demographic and clinical characteristics had no
statistically significant correlation with troponin levels except for marginal trend for past
medical history of diabetes and hyperlipidemia with corresponding P values of 0.072
and 0.055. Twenty‑six patients had cTnI level more than 0.01 µg/L and only two patients
had cTnI level more than 0.11 µg/L. For laboratory results, only fasting blood sugar
had statistically significant correlation with patients’ cTnI level(r = 0.357, P = 0.0001).
Conclusion: Frequency of significant elevation of cTnI level in our asymptomatic
HD patients was very low and if such elevation is found in this population, it may be
considered as a sign of active CVD.
Keywords
Gangji AS. Waist‑to‑hip ratio, cardiovascular outcomes,
and death in peritoneal dialysis patients. Int J Nephrol
2010;2010:831243.
2. Babuin L, Jaffe AS. Troponin: The biomarker of choice for the
detection of cardiac injury. CMAJ 2005;173:1191‑202.
3. Buiten MS, de Bie MK, Rotmans JI, Dekker FW, van Buren M,
Rabelink TJ, et al. Serum cardiac troponin‑I is superior to
troponin‑T as a marker for left ventricular dysfunction in
clinically stable patients with end‑stage renal disease. PLoS
One 2015;10:e0134245.
4. Badero OJ, Salifu MO. Prediction of hemodynamically
significant coronary artery disease using troponin I
in hemodialysis patients presenting with chest pain:
A case‑control study. Cardiology 2009;114:292‑7.
5. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial
infarction redefined – A consensus document of The Joint
European Society of Cardiology/American College of
Cardiology Committee for the redefinition of myocardial
infarction. J Am Coll Cardiol 2000;36:959‑69.
6. Hickman PE, Potter JM, Aroney C, Koerbin G, Southcott E,
Wu AH, et al. Cardiac troponin may be released by ischemia
alone, without necrosis. Clin Chim Acta 2010;411:318‑23.
7. Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin
Pathol 2004;57:1025‑6.
8. Van Lente F, McErlean ES, DeLuca SA, Peacock WF, Rao JS,
Nissen SE. Ability of troponins to predict adverse outcomes
in patients with renal insufficiency and suspected acute
coronary syndromes: A case‑matched study. JAm Coll Cardiol
1999;33:471‑8.
9. Resic H, Ajanovic S, Kukavica N, Masnic F, Coric A. Plasma
levels of brain natriuretic peptides and cardiac troponin in
hemodialysis patients. Bosn J Basic Med Sci 2009;9:137‑41.
10. Ie EH, Klootwijk PJ, Weimar W, Zietse R. Significance of
acute versus chronic troponin T elevation in dialysis patients.
Nephron Clin Pract 2004;98:c87‑92.
11. Alivanis P, Giannikouris I, Kaligas G, ArvanitisA, Volanaki M,
Vogiatzis P, et al. Influence of different dialysis membrane
types on cardiac‑specific troponin T levels. PROCEEDINGS
of the 6th BANTAO Congress. BANTAO J 2003;1:89‑90.
12. Iliou MC, Fumeron C, Benoit MO, Tuppin P, Courvoisier CL, Calonge VM, et al. Factors associated with increased serum
levels of cardiac troponins T and I in chronic haemodialysis
patients: Chronic haemodialysis and new cardiac markers
evaluation (CHANCE) study. Nephrol Dial Transplant
2001;16:1452‑8.
13. Gaze DC, Collinson PO. Cardiac troponin I but not cardiac
troponin T adheres to polysulfone dialyser membranes
in an in vitro haemodialysis model: Explanation for lower
serum cTnI concentrations following dialysis. Open Heart
2014;1:e000108.
14. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA,
Dvorak DL, et al. Acute myocardial infarction and renal
dysfunction: A high‑risk combination. Ann Intern Med
2002;137:563‑70.
15. Brouns R, De Deyn PP. Neurological complications in renal
failure: A review. Clin Neurol Neurosurg 2004;107:1‑16.
16. Xanthos T, Ekmektzoglou KA, Papadimitriou L. Reviewing
myocardial silent ischemia: Specific patient subgroups. Int J
Cardiol 2008;124:139‑48.
17. Marchant B, Umachandran V, Stevenson R, Kopelman PG,
Timmis AD. Silent myocardial ischemia: Role of subclinical
neuropathy in patients with and without diabetes. J Am Coll
Cardiol 1993;22:1433‑7.
18. Mohi‑ud‑din K, Bali HK, Banerjee S, Sakhuja V, Jha V.
Silent myocardial ischemia and high‑grade ventricular
arrhythmias in patients on maintenance hemodialysis. Ren
Fail 2005;27:171‑5.
19. McLaurin MD, Apple FS, Falahati A, Murakami MM,
Miller EA, Sharkey SW. Cardiac troponin I and creatine
kinase‑MB mass to rule out myocardial injury in hospitalized
patients with renal insufficiency. Am J Cardiol 1998;82:973‑5.
20. Hussein M, Mooij J, Roujouleh H, Al Shenawi O. Cardiac
troponin‑I and its prognostic significance in a dialysis
population. Hemodial Int 2004;8:332‑7.
21. Segre CA, Hueb W, Garcia RM, Rezende PC, Favarato D,
Strunz CM, et al. Troponin in diabetic patients with and
without chronic coronary artery disease. BMC Cardiovasc
Disord 2015;15:72.
22. Lin‑Tan DT, Lin JL, Wang LH, Wang LM, Huang LM,
Liu L, et al. Fasting glucose levels in predicting 1‑year
all‑cause mortality in patients who do not have diabetes
and are on maintenance hemodialysis. J Am Soc Nephrol
2007;18:2385‑91.
23. Snit M, Dwornicki M, Zukowska‑Szczechowska E,
Grzeszczak W. Impact of glycemic control on survival of
diabetic patients on chronic regular hemodialysis: A 7‑year
observational study. Diabetes Care 2007;30:189.
24. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y,
Tahara H, et al. Impact of glycemic control on survival of
diabetic patients on chronic regular hemodialysis: A 7‑year
observational study. Diabetes Care 2006;29:1496‑500.
25. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF,
Kopple JD, Kalantar‑Zadeh K. Association between serum
lipids and survival in hemodialysis patients and impact of
race. J Am Soc Nephrol 2007;18:293‑303.
26. Kalantar‑Zadeh K, Block G, Humphreys MH, Kopple JD.
Reverse epidemiology of cardiovascular risk factors in
maintenance dialysis patients. Kidney Int 2003;63:793‑808.
)